U.S. Markets closed

Report: Developing Opportunities within Owens & Minor, Zosano Pharma, Organovo, Summit Materials, Ralph Lauren, and Clearside Biomedical — Future Expectations, Projections Moving into 2018

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Owens & Minor, Inc. (OMI), Zosano Pharma Corporation (ZSAN), Organovo Holdings, Inc. (ONVO), Summit Materials, Inc. (SUM), Ralph Lauren Corporation (RL), and Clearside Biomedical, Inc. (CLSD), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

OMI DOWNLOAD: http://Fundamental-Markets.com/register/?so=OMI
ZSAN DOWNLOAD: http://Fundamental-Markets.com/register/?so=ZSAN
ONVO DOWNLOAD: http://Fundamental-Markets.com/register/?so=ONVO
SUM DOWNLOAD: http://Fundamental-Markets.com/register/?so=SUM
RL DOWNLOAD: http://Fundamental-Markets.com/register/?so=RL
CLSD DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLSD

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Owens & Minor, Inc. (OMI), Zosano Pharma Corporation (ZSAN), Organovo Holdings, Inc. (ONVO), Summit Materials, Inc. (SUM), Ralph Lauren Corporation (RL), and Clearside Biomedical, Inc. (CLSD) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 6th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

OWENS & MINOR, INC. (OMI) REPORT OVERVIEW

Owens & Minor's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Owens & Minor reported revenue of $2,389.83MM vs $2,368.36MM (up 0.91%) and basic earnings per share $0.38 vs $0.44 (down 13.64%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Owens & Minor reported revenue of $9,318.28MM vs $9,723.43MM (down 4.17%) and basic earnings per share $1.20 vs $1.76 (down 31.82%). Owens & Minor is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.41. The estimated EPS forecast for the next fiscal year is $2.24 and is expected to report on February 13th, 2019.

To read the full Owens & Minor, Inc. (OMI) report, download it here: http://Fundamental-Markets.com/register/?so=OMI

-----------------------------------------

ZOSANO PHARMA CORPORATION (ZSAN) REPORT OVERVIEW

Zosano Pharma's Recent Financial Performance

Zosano Pharma is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$9.20. The estimated EPS forecast for the next fiscal year is -$18.00 and is expected to report on March 7th, 2018.

To read the full Zosano Pharma Corporation (ZSAN) report, download it here: http://Fundamental-Markets.com/register/?so=ZSAN

-----------------------------------------

ORGANOVO HOLDINGS, INC. (ONVO) REPORT OVERVIEW

Organovo's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Organovo reported revenue of $1.15MM vs $1.15MM (up 0.17%) and basic earnings per share -$0.07 vs -$0.09. For the twelve months ended March 31st, 2017 vs March 31st, 2016, Organovo reported revenue of $4.23MM vs $1.48MM (up 185.23%) and basic earnings per share -$0.39 vs -$0.43. Organovo is expected to report earnings on June 6th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is -$0.25 and is expected to report on June 6th, 2018.

To read the full Organovo Holdings, Inc. (ONVO) report, download it here: http://Fundamental-Markets.com/register/?so=ONVO

-----------------------------------------

SUMMIT MATERIALS, INC. (SUM) REPORT OVERVIEW

Summit Materials' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Summit Materials reported revenue of $490.02MM vs $422.97MM (up 15.85%) and basic earnings per share $0.43 vs $0.14 (up 217.36%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Summit Materials reported revenue of $1,932.58MM vs $1,626.06MM (up 18.85%) and basic earnings per share $1.12 vs $0.52 (up 115.38%). Summit Materials is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.49. The estimated EPS forecast for the next fiscal year is $1.96 and is expected to report on February 13th, 2019.

To read the full Summit Materials, Inc. (SUM) report, download it here: http://Fundamental-Markets.com/register/?so=SUM

-----------------------------------------

RALPH LAUREN CORPORATION (RL) REPORT OVERVIEW

Ralph Lauren's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Ralph Lauren reported revenue of $1,641.80MM vs $1,714.60MM (down 4.25%) and basic earnings per share -$1.00 vs $0.98. For the twelve months ended March 31st, 2017 vs March 31st, 2016, Ralph Lauren reported revenue of $6,652.80MM vs $7,405.20MM (down 10.16%) and basic earnings per share -$1.20 vs $4.65. Ralph Lauren is expected to report earnings on May 17th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.89. The estimated EPS forecast for the next fiscal year is $6.08 and is expected to report on May 17th, 2018.

To read the full Ralph Lauren Corporation (RL) report, download it here: http://Fundamental-Markets.com/register/?so=RL

-----------------------------------------

CLEARSIDE BIOMEDICAL, INC. (CLSD) REPORT OVERVIEW

Clearside Biomedical's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Clearside Biomedical reported revenue of $0.16MM vs $0.01MM (up 3,000.00%) and basic earnings per share -$0.72 vs -$0.28. Clearside Biomedical is expected to report earnings on March 13th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.45. The estimated EPS forecast for the next fiscal year is -$2.46 and is expected to report on March 13th, 2018.

To read the full Clearside Biomedical, Inc. (CLSD) report, download it here: http://Fundamental-Markets.com/register/?so=CLSD

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.